ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PACB / forecast
CTKB (45) NAUT (43) ALMR (55) LAB (27) ⌘ Pro Terminal →

Pacific Biosciences of California Inc. (PACB) 12-Month Stock Forecast & Price Target Cone

$2.35 -9.98% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.30

Pacific Biosciences of California Inc. (PACB) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $809.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PACB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PACB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Pacific Biosciences of California Inc. (NASDAQ: PACB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $2.35 (-9.98% 1D, market cap $809.7M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PACB ranks #387 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PACB compare to CTKB and NAUT in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), PACB carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 28.6%, and ROIC of -35.0%. By comparison, CTKB (Cytek Biosciences Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -12.7%, cap $796.8M) and NAUT (Nautilus Biotechnology Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $347.7M). Among the 5-stock peer group, PACB leads on earnings multiple (N/A) while CTKB leads on capital efficiency (-12.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PACB?
▼

Per PACB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001299130), Pacific Biosciences of California Inc. generated $160.0M in revenue (+3.9% YoY), -$546.4M in net income, and -$113.9M in free cash flow against $784.1M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.30 (-1.99%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510044
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D-
Cash (9)Whales (16)SEC (8)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-6.4% Base Target
$4 Bull$2 Base$2 Bear
📬 FREE PACB RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PACB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (44/100 Composite)
🔍 WHY PACB SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (36% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (20% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 28.6% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
36
Grade E$2.05-4.4% Next Q
Q2 (-2Q)
39
Grade E$1.96+25% Next Q
Q3 (-1Q)
41
Grade D$2.45-4.1% Next Q
Current
44
Grade D$2.35-6.5% Hist 90D α
Trajectory: E (36) → D (44)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PACB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PACB currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.89) and Max Pain ($2.47) forces dealer call-delta covering toward $3.61.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PACB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PACB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 44%NO 56%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your PACB Position Size: $10,000

Shares at $2.35: 4255.3 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $1.72
$7,319
$-2,681 (-26.8%)
12M Consensus BaseTarget $2.20
$9,362
$-638 (-6.4%)
12M Bull Case BreakoutTarget $3.61
$15,362
+$5,362 (+53.6%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$274%A
Goldman SachsSector Coverage LeadUNDERPERFORM$369%B
JP MorganUS Large-Cap ResearchSELL$258%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PACB)

  • ✓Walkthrough of PACB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PACB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +51.61%📐 HORIZONTAL RANGE
2026-11-03O $2.90H $2.90L $2.35C $2.35VOL 13.74M
RES: $3.83SUP: $1.05SMA50: $1.89SMA200: $1.62
$3.61$2.92$2.23$1.54$0.86RES $3.83SUP $1.05$2.352026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PACB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PACB Butterfly Map → + Track PACB →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +3.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PACB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PACB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PACB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PACB)

Health Care Rank #387 of 1015 ⚔️ CTKB vs PACB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PACB vs. CTKB, NAUT, ALMR, LAB)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Pacific Biosciences of California Inc. (PACB) ranks #387 by composite RQD confidence (44/100, grade D) and #380 by equity capitalization ($809.7M). Within this direct 5-issuer industry benchmark cohort, PACB leads on earnings valuation at N/A trailing P/E, while CTKB leads on capital efficiency and profitability with -12.7% ROIC and 51.8% gross margin. ALMR currently holds the highest overall quantitative score in the immediate peer group at 55/100 (D+) compared with PACB at 44/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PACB ACTIVE
Pacific Biosciences of California Inc.
D 44/100 — 28.6% -35.0% -9.98% $809.7M Benchmark Subject
CTKB
Cytek Biosciences Inc.
D 45/100 — 51.8% -12.7% -5.87% $796.8M /ctkb-vs-pacb →
NAUT
Nautilus Biotechnology Inc.
D- 43/100 — — -35.0% -14.47% $347.7M /naut-vs-pacb →
ALMR
Alamar Biosciences Inc.
D+ 55/100 — — — -5.42% $2.12B /almr-vs-pacb →
LAB
Standard BioTools Inc.
E 27/100 — 49.9% -28.7% -0.02% $240.7M /lab-vs-pacb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001299130 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pacific Biosciences of California Inc. (PACB) reported GAAP revenue of $160.0M (+3.9% vs. FY2024 revenue of $154.0M , and -82.9% cumulative change since FY2023) , GAAP net income of -$546.4M, operating cash flow of -$111.2M, and free cash flow of -$113.9M (+46.3% YoY). On the balance sheet, PACB closed FY2025 with $784.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $160.0M -$546.4M -$111.2M -$113.9M $784.1M —
FY2024 (FY) 2024-12-31 $154.0M -$309.9M -$206.1M -$212.2M $1.26B —
FY2023 (FY) 2023-12-31 $936.5M -$306.7M -$259.2M -$259.2M — —

3. PACB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PACB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Pacific Biosciences of California Inc. (NASDAQ: PACB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $2.35 (-9.98% 1D, market cap $809.7M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PACB ranks #387 in composite RQD confidence.

How does PACB compare to CTKB and NAUT in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), PACB carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 28.6%, and ROIC of -35.0%. By comparison, CTKB (Cytek Biosciences Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -12.7%, cap $796.8M) and NAUT (Nautilus Biotechnology Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $347.7M). Among the 5-stock peer group, PACB leads on earnings multiple (N/A) while CTKB leads on capital efficiency (-12.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PACB?

Per PACB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001299130), Pacific Biosciences of California Inc. generated $160.0M in revenue (+3.9% YoY), -$546.4M in net income, and -$113.9M in free cash flow against $784.1M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PACB trading relative to its 50-day, 200-day, and 52-week technical levels?

PACB last traded at $2.35 (-9.98% on volume of 9,099,762 shares), positioning the stock +24.34% above its 50-day simple moving average ($1.89) and +45.06% above its 200-day simple moving average ($1.62). Across its 52-week range of $1.07 to $3.44, PACB sits at the 54.0% percentile with a 14-day RSI of 58.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.06 to $2.64).

Direct Sub-Reports: PACB RQD Cockpit PACB 12M Forecast PACB Earnings & Move PACB Dividends & DRIP PACB Insiders & 13F PACB Whale Options PACB Profit Sankey PACB News & Why
ROARABLE RATING BRIEF • RQD 44/100 (D) ✓ SEC XBRL & RQD VERIFIED

PACB — Pacific Biosciences of California Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Pacific Biosciences of California Inc. (PACB) earns a live Roarable RQD composite score of 44/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $2.35 (-9.98% 1D, market capitalization $809.7M).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 28.6%, operating margin of -60.0%, and free cash flow yield of -12.64%.
  • Whale 13F & Options Flow (16/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Pacific Biosciences of California Inc. (PACB) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Laboratory Analytical Instruments. The profile identifies its market capitalization as $0.9B. Revenue reported in the SEC financials was $160.0M for FY 2025.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Pacific Biosciences of California Inc. (PACB) reported $160.0M in annual revenue (up from $154.0M in FY2024, +3.9% YoY) and -$546.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($936.5M revenue, -$306.7M net income) through FY2025, PACB scaled operating cash flow to -$111.2M and free cash flow to -$113.9M, backed by $784.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 44/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -12.64% and institutional whale pillar of 16/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $1.07 – $3.44 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source data therefore does not identify upstream suppliers, downstream customers, or cross-sector correlations. Investors should note that the absence of mapped links means the sector sensitivity referenced in the RQD Macro Regime pillar is not traced to specific counterparties in this dataset.

  • Key Question #1: Can PACB sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Laboratory Analytical Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $160.0M and free cash flow of -$113.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is PACB's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PACB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Pacific Biosciences of California Inc. (PACB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PACB Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PACB Bull vs. Bear Conversation Board — What's Your Call at $2.35?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PACB 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PACB:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $3.31 (+26.8%)
📌 Pinned Debate

Institutional accumulation and options positioning score 16/20, the strongest pillar in the RQD rating.

Institutional accumulation and options positioning score 16/20, the strongest pillar in the RQD rating.. When you look under the hood at PACB, Fundamental Cash Engine is 9/20 with 28.6% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (16/20) has been quietly accumulating below $3.44. My 12M target is $3.31.

CapAlloc_Nerd 🐂 BULL

@ForensicBear Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Laboratory Analytical Instruments. If gross margin (28.6%) holds, EPS grows into the multiple faster than bears think.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $2.01 (-23.0%)
Spot @ $2.61

Free cash flow yield of -12.64% and ROIC of -35% show the business consuming cash relative to its market value.

Careful chasing PACB at $2.61. Free cash flow yield of -12.64% and ROIC of -35% show the business consuming cash relative to its market value.. Gross margin is 28.6%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $2.01 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%